{"prompt": "['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '155', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '[Lopes, G., et al 2018]', 'Lopes G, Wu Y, Kudaba I, Kowalski', '[04Y5G9]', 'D, Cho BC, Castro G, et al.', 'Pembrolizumab (pembro) versus', 'platinum-based chemotherapy', '(chemo) as first-line therapy for', 'advanced/metastatic NSCLC with a', 'PD-L1 tumor proportion score (TPS)', '> 1%: open-label, phase 3', 'KEYNOTE-042 study [abstract].', 'Presented at: The American Society of', 'Clinical Oncology (ASCO) Annual', 'Meeting; 2018 Jun 1-5; Chicago, IL. J', 'Clin Oncol. 2018;36(suppl). Abstract', 'no. LBA4.', '[Makker, V., et al 2018]', 'Makker V, Rasco D, Vogelzang NJ,', '[04YJ9J]', 'Messing M, Brose MS, Cohn AL, et', 'al. Lenvatinib + Pembrolizumab in', 'patients with advanced endometrial', 'cancer: updated results. Poster session', 'presented at: 2018 American Society', 'of Clinical Oncology (ASCO) Annual', 'Meeting; 2018 Jun 1-5; Chicago, IL.', 'Poster no. 5596.', '[Miettinen, O. 1985]', 'Miettinen O, Nurminen M.', '[00VMQY]', 'Comparative analysis of two rates.', 'Stat Med 1985;4:213-26.', '[National Cancer Institute 2018]', 'SEER*Stat [Internet]. Bethesda (MD): [0507C2]', 'National Cancer Institute. 2018.', 'Cancer stat facts: lung and bronchus', 'cancer; [about 12 screens]. Available', 'from:', 'https://seer.cancer.gov/statfacts/html/l', 'ungb.html.', '[Nishio, M., et al 2013]', 'Nishio M, Horai T, Horiike A,', '[04ZK34]', 'Nokihara H, Yamamoto N, Takahashi', 'T, et al. Phase 1 study of lenvatinib', 'combined with carboplatin and', 'paclitaxel in patients with non-small-', 'cell lung cancer. Br J Cancer.', '013;109:538-44.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '156', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '[Pickard, A. S., et al 2007]', 'Pickard AS, Neary MP, Cella D.', '[00W0FM]', 'Estimation of minimally important', 'differences in EQ-5D utility and VAS', 'scores in cancer. Health Qual Life', 'Outcomes 2007;5:1-8.', '[Rabin, R. 2001]', 'Rabin R, de Charro F. EQ-5D: a', '[03QM46]', 'measure of health status from the', 'EuroQol group. Ann Med', '2001;33:337-43.', '[Reck, M., et al 2016]', 'Reck M, Rodriguez-Abreu D,', '[04JNM3]', 'Robinson AG, Hui R, Csoszi T, Fulop', 'A, et al. Pembrolizumab versus', 'Chemotherapy for PD-L1-Positive', 'Non-Small-Cell Lung Cancer. N Engl', 'J Med. 2016 Oct 8. [Epub ahead of', 'print].', '[Seymour, L., et al 2017]', 'Seymour L, Bogaerts J, Perrone A,', '[04P9RV]', 'Ford R, Schwartz LH, Mandrekar S, et', 'al. iRECIST: guidelines for response', 'criteria for use in trials testing', 'immunotherapeutics. Lancet Oncol.', '2017 Mar;18(3):e143-52', '[Sulpher, J. A., et al 2013]', 'Sulpher JA, Owen SP, Hon H, Tobros', '[040565]', 'K, Shepherd FA, Sabri E, et al.', 'Factors influencing a specific', 'pathologic diagnosis of non-small-cell', 'lung carcinoma. Clin Lung Cancer.', '2013 May;14(3):238-44.', '[Tammela, T. 2010]', 'Tammela T, Alitalo K.', '[04XKRB]', 'Lymphangiogenesis: molecular', 'mechanisms and future promise. Cell.', '2010 Feb 19;140:460-76.', '[Wolchok, J. D., et al 2009]', \"Wolchok JD, Hoos A, O'Day S,\", '[00VMNZ]', 'Weber JS, Hamid O, Lebb\u00e9C, et al.', 'Guidelines for the evaluation of', 'immune therapy activity in solid', 'tumors: immune-related response', 'criteria. Clin Cancer Res', '2009;15(23):7412-20.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']\n\n###\n\n", "completion": "END"}